NEWS HIGHLIGHTSMedia Articles Related to Exelon (Rivastigmine)
New Neuroimaging Analysis Technique Identifies Impact Of Alzheimer's Disease Gene In Healthy Brains
Source: Genetics News From Medical News Today [2009.11.19]
Brain imaging can offer a window into risk for diseases such as Alzheimer's disease (AD). A study conducted at the University of Kansas School of Medicine demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD. The results of this study are published in the November 2009 issue of the Journal of Alzheimer's Disease.
Analyzing Structural Brain Changes In Alzheimer's Disease
Source: Medical Devices / Diagnostics News From Medical News Today [2009.11.18]
In a study that promises to improve diagnosis and monitoring of Alzheimer's disease, scientists at the University of California, San Diego have developed a fast and accurate method for quantifying subtle, sub-regional brain volume loss using magnetic resonance imaging (MRI). The study is published the week of November 16 in the Proceedings of the National Academy of Sciences (PNAS).
Special Issue Of Behavioural Neurology Focuses On Alzheimer's Disease
Source: MRI / PET / Ultrasound News From Medical News Today [2009.11.11]
With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense.
High Blood Pressure And Markers Of Inflammation In Blood More Common In Offspring Of Parents With Alzheimer's Disease
Source: Hypertension News From Medical News Today [2009.11.04]
High blood pressure, evidence of arterial disease and markers of inflammation in the blood in middle age appear more common in individuals whose parents have Alzheimer's disease than in individuals without a parental history of the condition, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Alzheimer's Disease: Home Safety Information
Source: MedicineNet Advance Medical Directives Specialty [2008.08.26]
Title: Alzheimer's Disease: Home Safety Information
Category: Diseases and Conditions
Created: 8/26/2008
Last Editorial Review: 8/26/2008
Published Studies Related to Exelon (Rivastigmine)
Rivastigmine in Parkinson's disease dementia. [2009.08]
Parkinson's disease has now evolved beyond what was considered to be a traditional motor disorder... A transdermal patch which gradually releases rivastigmine over the application period is now available for use in mild to moderate dementia associated with Parkinson's disease and Alzheimer's disease.
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. [2009.08]
OBJECTIVE: Evaluate the effect of sex and butyrylcholinesterase (BuChE) genotype on the incidence of Alzheimer's disease (AD), cognitive and functional decline, brain volume changes, and response to rivastigmine treatment in individuals with mild cognitive impairment (MCI)... CONCLUSION: Sex and BuChE genotype seem to differentially influence the type of decline in MCI patients, with more rapid progression of cognitive decline in male BuChE-K, and more incident AD and functional decline in female BuChE wt/wt. Cognitive decline in male BuChE-K and functional decline and incident AD in female BuChE wt/wt were significantly attenuated by rivastigmine. Rivastigmine treatment also significantly reduced ventricular expansion, whole-brain atrophy rate, and white matter loss in female BuChE wt/wt, suggesting a possible disease-modifying effect.
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. [2009.07]
BACKGROUND: Epidemiologic studies have identified several demographic factors, including gender, that may influence the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD). OBJECTIVE: This analysis aimed to develop a sensitive model for detecting treatment benefits in patients with MCI by controlling for factors that predict progression to AD. The study used this statistical modeling to investigate the effect of gender on treatment response in patients with MCI... CONCLUSIONS: In these patients with MCI, a significant decrease in the risk for progression to AD was found with rivastigmine over 3 to 4 years. The proportion of women whose disease progressed to AD was significantly lower in the rivastigmine group than the placebo group (P = 0.046). This effect was not found in men. These data suggest that prospectively adjusting for predictive factors could lead to a more accurate estimation of treatment benefits in future studies of MCI.
Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. [2009.07]
BACKGROUND: Impairment of multiple neurotransmitter networks, including acetylcholine, may contribute to the cognitive impairment in patients with Parkinson disease with dementia (PDD). Therefore, cholinesterase inhibitors might improve cognitive function in PDD. On the other hand, enhancing cholinergic function could plausibly worsen features of parkinsonism. OBJECTIVE: To determine if oral cholinesterase inhibitors improve measures of cognitive outcome and are tolerated by people with PDD... CONCLUSION: Rivastigmine therapy for PDD is associated with significant tradeoffs in efficacy and adverse effects. Carefully monitored trials of rivastigmine may provide meaningful benefits for a minority of PDD patients.
A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught? [2009.06]
CONCLUSIONS: A weak trend favouring rivastigmine for chronic symptoms of TBI was observed. The clinical significance of the results and the problems in conducting drug trials for chronic TBI symptoms are discussed.
Clinical Trials Related to Exelon (Rivastigmine)
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease [Completed]
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible
patients will receive open-label treatment with rivastigmine capsules plus memantine tablets
as add on therapy. This study is designed to evaluate the safety and tolerability of add on
therapy with memantine to rivastigmine capsules in patients with probable AD (MMSE 10-20)
Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients [Terminated]
The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled,
doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or
haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium,
severity of delirium, length of ICU/hospital stay and side effects between the different
interventions.
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment [Completed]
This is a prospective, multicenter, open-label study. Following screening and baseline
assessments, eligible patients will be switched to rivastigmine and will enter the 16 week
run-in rivastigmine treatment phase. After completion of assessments at the end of the
run-in phase, patients who were not sufficiently stabilized on rivastigmine alone will
receive add-on memantine to their rivastigmine treatment; patients who were stabilized on
rivastigmine alone will have completed and be discontinued from the study.
Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment [Completed]
This study is designed to investigate the efficacy and safety of rivastigmine compared with
placebo in patients with traumatic brain injury and cognitive impairment.
Rivastigmine Capsules in Patients With Probable Vascular Dementia [Completed]
The goal of this research study is to evaluate, in the open-label extension phase, the
effectiveness, tolerability and safety of rivastigmine capsules in males and females between
the ages of 50 and 85 years old with probable vascular dementia.
|
